home / stock / ards / ards news

ARDS News and Press, Aridis Pharmaceuticals Inc. From 08/12/19

Stock Information
Company Name: Aridis Pharmaceuticals Inc.
Stock Symbol: ARDS
Market: NASDAQ
Website: aridispharma.com
Menu
ARDS ARDS Quote ARDS Short ARDS News ARDS Articles ARDS Message Board
Get ARDS Alerts

News, Short Squeeze, Breakout and More Instantly...
ARDS - Aridis Pharmaceuticals Announces Second Quarter 2019 Results

SAN JOSE, Calif. , Aug. 12, 2019 /PRNewswire/ --  Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of targeted immunotherapies using fully human monoclonal antibodies (mAbs) to treat life-threatening bacterial infectio...
ARDS - Aridis Pharmaceuticals Enters Into Equity Purchase and Option Agreements with The Serum Institute of India, Ltd for Exclusive License to Products and MabIgX® Platform Technology

SAN JOSE, Calif. , July 30, 2019 /PRNewswire/ --  Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of targeted immunotherapies using fully human monoclonal antibodies (mAbs) to treat life-threatening bacterial infectio...

ARDS - Aridis Pharmaceuticals Receives Orphan Drug Designation From the European Medicines Agency for AR-501

SAN JOSE, Calif. , July 19, 2019 /PRNewswire/ --  Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) announced today that the European Medicines Agency (EMA) has granted Orphan Drug Designation to AR-501, the Company's inhaled formulation of gallium citrate for treatment of lung infection ...

ARDS - Aridis Pharmaceuticals Receives Orphan Drug Designation for AR-501

SAN JOSE, Calif. , June 27, 2019 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of targeted immunotherapies for life-threatening bacterial infections, announced today that the U.S. Food and Drug Administr...
ARDS - Aridis Pharmaceuticals Appoints Dr. Susan Windham-Bannister to Board of Directors

SAN JOSE, Calif. , June 10, 2019 /PRNewswire/ --  Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of targeted immunotherapies using fully human monoclonal antibodies (mAbs) to treat life-threatening bacterial infectio...

ARDS - Aridis Pharmaceuticals misses by $0.06, beats on revenue

Aridis Pharmaceuticals (NASDAQ: ARDS ): Q1 GAAP EPS of -$0.99 misses by $0.06 . More news on: Aridis Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

ARDS - Aridis Pharmaceuticals Announces First Quarter 2019 Results

SAN JOSE, Calif. , May 14, 2019 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of targeted immunotherapies using fully human monoclonal antibodies (mAbs) to treat life-threatening bacterial infections, to...
ARDS - Aridis Pharmaceuticals reports Q4 results

Aridis Pharmaceuticals (NASDAQ: ARDS ): Q4 GAAP EPS of -$0.67. More news on: Aridis Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

ARDS - Aridis Pharmaceuticals Announces 2018 Fourth Quarter and Year-End Financial Results and Business Update

SAN JOSE, Calif. , March 28, 2019 /PRNewswire/ --  Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of targeted immunotherapies using fully human monoclonal antibodies (mAbs) to treat life-threatening bacterial infecti...

ARDS - Those Ticking Clocks (Stocks To Watch Podcast)

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you can...
Previous 10 Next 10